Yoshihiro Kushihara, Shota Tanaka, Yukari Kobayashi, Koji Nagaoka, Miyu Kikuchi, Takahide Nejo, Erika Yamazawa, Shohei Nambu, Kazuha Kugasawa, Hirokazu Takami, et al. Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression. Frontiers in immunology. 2024. 15. 1328375-1328375
Taijun Hana, Akitake Mukasa, Masashi Nomura, Genta Nagae, Shogo Yamamoto, Kenji Tatsuno, Hiroki Ueda, Shiro Fukuda, Takayoshi Umeda, Shota Tanaka, et al. Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas. Cancer Science. 2024
Yu Teranishi, Satoru Miyawaki, Masahiro Nakatochi, Atsushi Okano, Kenta Ohara, Hiroki Hongo, Daiichiro Ishigami, Yu Sakai, Daisuke Shimada, Shunsaku Takayanagi, et al. Meningiomas in patients with neurofibromatosis type 2 predominantly comprise 'immunogenic subtype' tumours characterised by macrophage infiltration. Acta neuropathologica communications. 2023. 11. 1. 156-156
Daisuke Sato, Hirokazu Takami, Shunsaku Takayanagi, Masako Ikemura, Reiko Matsuura, Shota Tanaka, Nobuhito Saito. Intraventricular central neurocytoma molecularly defined as extraventricular neurocytoma: a case representing the discrepancy between clinicopathological and molecular classifications. Brain tumor pathology. 2023. 40. 4. 230-234
Ryohei Otani, Masachika Ikegami, Ryoji Yamada, Hirohisa Yajima, Shinji Kawamura, Sakura Shimizu, Shota Tanaka, Shunsaku Takayanagi, Hirokazu Takami, Tatsuro Yamaguchi. PTPN11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort. Journal of neuro-oncology. 2023. 164. 1. 221-229